Global CAR T-Cell Therapy for Multiple Myeloma Market Growth (Status and Outlook) 2023-2029

Global CAR T-Cell Therapy for Multiple Myeloma Market Growth (Status and Outlook) 2023-2029

CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. they are used as an individual's own cells and re-engineers them to fight cancer. Though the market has witnessed several positive results of the clinical trial in the recent years, it is yet to receive an approval of the first CAR T-cell therapy for multiple myeloma. 

LPI (LP Information)' newest research report, the “CAR T-Cell Therapy for Multiple Myeloma Industry Forecast” looks at past sales and reviews total world CAR T-Cell Therapy for Multiple Myeloma sales in 2022, providing a comprehensive analysis by region and market sector of projected CAR T-Cell Therapy for Multiple Myeloma sales for 2023 through 2029. With CAR T-Cell Therapy for Multiple Myeloma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR T-Cell Therapy for Multiple Myeloma industry.

This Insight Report provides a comprehensive analysis of the global CAR T-Cell Therapy for Multiple Myeloma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CAR T-Cell Therapy for Multiple Myeloma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CAR T-Cell Therapy for Multiple Myeloma market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR T-Cell Therapy for Multiple Myeloma and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR T-Cell Therapy for Multiple Myeloma.

The global CAR T-Cell Therapy for Multiple Myeloma market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

The increasing number of collaborations or licensing agreements between companies and research institute, will induce the involvement of more investors in this area. Car T-cell therapy for multiple myeloma has identified that most of the pipeline molecules in multiple myeloma are currently in the pre-clinical development stage. KMA.CAR-T the drug is under development by the company HaemaLogiX. This monotherapy drug is currently in the pre-clinical stage and the company has already signed an agreement with Westmead Institute for Medical Research.

This report presents a comprehensive overview, market shares, and growth opportunities of CAR T-Cell Therapy for Multiple Myeloma market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Monotherapy
Combination Therapy

Segmentation by application
Multiple Myeloma
Refractory or Relapsed Multiple Myeloma

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Juno Therapeutics
Kite Pharma
Novartis
Collectis

Please note: The report will take approximately 2 business days to prepare and deliver.